Evidence map›Paper›PMID 30389093›Full record

ArticleCellular immunology2019

In vivo administration of recombinant BTNL2-Fc fusion protein ameliorates graft-versus-host disease in mice.

Cheng Cui, Xiaohong Tian, Yujun Lin, Min Su, Qingquan Chen, Shao-Yuan Wang, Laijun Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cheng CuiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; Department of Physiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning, China.
Xiaohong TianDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Yujun LinDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Min SuDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Qingquan ChenDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.
Shao-Yuan WangFujian Institute of Hematology, Hematology Department of Fujian Medical University Union Hospital, China.
Laijun LaiDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, United States; University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, CT, United States. Electronic address: laijun.lai@uconn.edu.

Funding

Transplantation of ESC-derived thymic epithelial progenitors expressing autoantigen(s) ameliorating experimental autoimmune encephalomyelitisR01AI123131 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI LAI, LAIJUN · 2016 to 2020
$1.9M
NIAID NIH HHS R01 AI123131
6 · The paper itself

Abstract

Although hematopoietic stem cell transplantation (HSCT) has been widely used in the treatment of many diseases, graft-versus-host disease (GVHD) remains a major complication after allogeneic HSCT. Butyrophilin-like 2 (BTNL2) protein has been reported to have the ability to inhibit T cell proliferation in vitro; its ability to inhibit T cell responses in vivo has not been determined. We show here that in vivo administration of recombinant BTNL2-IgG2a Fc (rBTNL2-Ig) fusion protein ameliorates GVHD in mice. This is related to the ability of rBTNL2-Ig to inhibit T cell proliferation, activation and Th1/Th17 cytokine production in vivo. Furthermore, rBTNL2-Ig treatment increases the generation of regulatory T cells. Our results suggest that rBTNL2-Ig has the potential to be used in the prevention and treatment of patients with GVHD.

Indexed as

AnimalsButyrophilinsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunoglobulin Fc FragmentsImmunoglobulin GLymphocyte ActivationMiceMice, Inbred BALB CMice, Inbred C57BLRecombinant Fusion ProteinsTh17 CellsTh1 CellsT-Lymphocytes, RegulatoryTransplantation, HomologousBTNL2 protein, humanBTNL2 protein, mouseButyrophilinsImmunoglobulin Fc FragmentsImmunoglobulin GRecombinant Fusion ProteinsActivationButyrophilin-like 2Graft-versus-host diseaseHematopoietic stem cell transplantationRegulatory T cellsT cell proliferation

Identifiers

PMID30389093
PMCPMC6368466

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.